Diamonds and Dogs


Viking Therapeutics (VKTX) charging forward. The biotech is up 78% thanks to a positive mid-stage result for its experimental nonalcoholic steatohepatitis (NASH) medicine VK2809. Most critically, the drug seems to compare favorably to Madrigal Pharmaceuticals'MGL-3196 drug in terms of both safety and efficacy. The key takeaway here is that VK2809 now appears not only to be a viable NASH candidate, but it could be a best-in-class medicine to boot. That's a big deal, because the NASH market is forecast to reach a whopping $35 billion in sales over the next decade

A big whiff from Fed Ex (FDX). FedEx is down 4% after missing earnings estimates by 34 cents. Sales rose 11.5% year/year to $17.05 billion ahead of estimates and guidance was inline. But investors are focusing on the lower profits due to higher labor costs, higher fuel and commodity costs and currency issues. FedEx also said that economic activity is beginning to moderate in China as uncertainty increases around U.S. tariffs. The direct U.S.-China trade lane represents only about 2 percent of FedEx's total sales.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.